Core Viewpoint - Anke Biotechnology has entered into a strategic cooperation with its affiliate, Boshengji Pharmaceutical Technology, to exclusively promote and sell the PA3-17 injection product in Greater China after its market launch [1][2]. Group 1: Strategic Cooperation - Anke Biotechnology and Boshengji Pharmaceutical signed a framework agreement for exclusive agency rights concerning the PA3-17 injection product in Greater China, effective November 11, 2025 [1]. - The agreement outlines the responsibilities for sales and promotion of the PA3-17 injection product once it is launched [1]. Group 2: Product Details - PA3-17 injection is the world's first targeted CD7 autologous CAR-T cell therapy product approved for clinical trials, developed by Boshengji's subsidiary [2]. - The initial indication for PA3-17 is for the treatment of adult relapsed and refractory CD7-positive hematologic malignancies [2]. - The product has been included in the list of breakthrough therapies by the National Medical Products Administration and has entered a critical Phase II clinical trial [2]. Group 3: Future Collaboration - Boshengji has committed to prioritizing Anke Biotechnology as the exclusive agency for future product launches, ensuring long-term collaboration for sales and promotion [2].

Core Viewpoint - Anke Bio (安科生物) has entered a strategic partnership with Boshengji Pharmaceutical Technology (博生吉医药科技) to exclusively distribute the PA3-17 injection product in Greater China, which is a CAR-T cell therapy targeting CD7 for treating certain blood cancers [1] Group 1: Partnership Details - Anke Bio signed a framework agreement for exclusive agency rights regarding the PA3-17 injection product on November 11 [1] - The agreement includes provisions for long-term cooperation in sales and promotion of the PA3-17 injection in the Greater China market [1] - A formal exclusive agency agreement will be signed after the product's market application is submitted [1] Group 2: Product Information - PA3-17 injection is the first globally approved CAR-T cell therapy targeting CD7, developed by Boshengji's subsidiary [1] - The initial indication for PA3-17 is for adult patients with relapsed or refractory CD7-positive hematologic malignancies [1] - The product has been included in the list of breakthrough therapies by the National Medical Products Administration (NMPA) and is currently in critical Phase II clinical trials [1] Group 3: Future Collaboration - Boshengji has committed to prioritizing Anke Bio as the exclusive agency for future product launches [1] - Anke Bio will be responsible for the promotion and sales of these products post-launch [1]

Core Viewpoint - Anke Biotech (300009.SZ) is strengthening its strategic position in the innovative drug sector by increasing its investment in its affiliate, Boshengji Pharmaceutical Technology (Suzhou) Co., Ltd. [1] Group 1: Investment Details - The company plans to invest 30 million RMB of its own funds to increase its stake in Boshengji by subscribing to the newly registered capital of 119,062 RMB [1] - After the completion of this capital increase, the company will hold a 21.4121% equity stake in Boshengji [1]

智通财经APP讯，安科生物(300009.SZ)发布公告，为推动参股公司博生吉医药科技(苏州)有限公司(以下 简称"博生吉公司")旗下PA3-17 注射液产品的销售与推广，公司与博生吉公司达成战略合作，于2025年 11月11日签署《关于CD7-CAR-T(PA3-17 注射液)等产品独家代理框架协议》，约定PA3-17注射液产品 上市后大中华区(中国大陆及港澳台地区)独家代理的相关事宜。 本次独家代理合作旨在充分整合双方优势资源，实现协同发展的合作效应。公司通过独家代理模式可快 速引入创新药产品，填补现有产品在CAR-T细胞治疗领域的空白，进一步丰富公司产品矩阵，提升公司 在创新药市场的核心竞争力。 PA3-17注射液是博生吉公司全资子公司博生吉安科细胞技术有限公司自主研发的全球首款获得新药临 床试验批准的靶向CD7的自体CAR-T细胞治疗产品，首个适应症为用于治疗成人复发、难治性CD7阳性 血液淋巴系统恶性肿瘤。PA3-17注射液已被国家药品监督管理局药品审评中心(CDE)纳入突破性治疗品 种名单，并进入关键性II期临床试验。 博生吉公司拟委托公司就PA3-17注射液产品未来在大中华区市场销售、推广开展长 ...

博生吉公司拟委托公司就PA3-17注射液产品未来在大中华区市场销售、推广开展长期合作，待产品提 交上市申请后，双方将另行签订正式的独家代理协议。同时，博生吉公司承诺，其后续其他产品上市 后，将优先选择公司作为独家代理机构，由公司负责产品上市后的推广与销售工作。 本次独家代理合作旨在充分整合双方优势资源，实现协同发展的合作效应。公司通过独家代理模式可快 速引入创新药产品，填补现有产品在CAR-T细胞治疗领域的空白，进一步丰富公司产品矩阵，提升公司 在创新药市场的核心竞争力。 智通财经APP讯，安科生物(300009.SZ)发布公告，为推动参股公司博生吉医药科技(苏州)有限公司(以下 简称"博生吉公司")旗下PA3-17 注射液产品的销售与推广，公司与博生吉公司达成战略合作，于2025年 11月11日签署《关于CD7-CAR-T(PA3-17 注射液)等产品独家代理框架协议》，约定PA3-17注射液产品 上市后大中华区(中国大陆及港澳台地区)独家代理的相关事宜。 PA3-17注射液是博生吉公司全资子公司博生吉安科细胞技术有限公司自主研发的全球首款获得新药临 床试验批准的靶向CD7的自体CAR-T细胞治疗产品，首个 ...

Group 1 - The core point of the article is that Anke Bio (SZ 300009) announced a board meeting to discuss a framework agreement with Boshengji Pharmaceutical Technology (Suzhou) Co., Ltd. regarding exclusive agency and related transactions [1] - Anke Bio's revenue composition for the first half of 2025 shows that gene-engineered drugs account for 73.51%, other businesses for 16.77%, and external patches for 9.72% [1] - As of the report, Anke Bio's market capitalization is 18.7 billion yuan [1]

Core Viewpoint - The company has signed an exclusive agency framework agreement with Boshengji Company for the product CD7-CAR-T (PA3-17 injection) in the Greater China region, aiming for collaborative development and resource integration [1] Group 1 - The agreement was signed on November 11, 2025 [1] - The exclusive agency pertains to the product PA3-17 injection after its market launch [1] - The collaboration is intended to leverage the strengths of both parties for synergistic growth [1]

Core Viewpoint - The company announced a strategic partnership with Boshengji to exclusively distribute the PA3-17 injection product in Greater China, enhancing its product portfolio and competitive edge in the innovative drug market [1] Group 1: Strategic Partnership - The company has signed a framework agreement for exclusive agency rights regarding the PA3-17 injection product in Greater China, which includes mainland China and Hong Kong, Macau, and Taiwan [1] - This partnership is aimed at integrating resources from both companies to enrich the product matrix [1] - The agreement has been approved by the company's board of directors and does not require shareholder approval [1] Group 2: Product Information - PA3-17 injection is the world's first CAR-T cell therapy product targeting CD7, developed by Boshengji [1] - The initial indication for PA3-17 is for the treatment of adult relapsed and refractory CD7-positive hematologic malignancies [1] - The agreement does not specify any financial details and is not expected to have a significant impact on the company's current operating performance [1]

一、以 3 票赞成，0 票反对，0 票弃权审议通过了《关于向博生吉医药科技 （苏州）有限公司增资暨关联交易的议案》 为夯实公司创新药领域的战略布局，强化公司核心竞争力，同意公司拟以自 有资金 3,000 万元人民币对博生吉医药科技（苏州）有限公司（以下简称"博生 吉公司"）进行增资，本次增资完成后，公司持有博生吉公司 21.4121%的股权。 根据《深圳证券交易所创业板股票上市规则》规定，本次交易构成关联交易。具 体内容详见同日披露于中国证监会指定创业板信息披露网站巨潮资讯网 （www.cninfo.com.cn）的相关公告。 证券代码：300009 证券简称：安科生物 公告编号：2025-060 安徽安科生物工程（集团）股份有限公司 关于第八届监事会第二十一次会议决议的公告 本公司及监事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 安徽安科生物工程（集团）股份有限公司（以下简称"公司"）第八届监事 会第二十一次会议于 2025 年 11 月 5 日以书面形式发出会议通知，2025 年 11 月 11 日上午 11:00 以现场及通讯会议的方式召开。应参会 3 人，实际参会 ...

证券代码：300009 证券简称：安科生物 公告编号：2025-058 安徽安科生物工程（集团）股份有限公司 关于向博生吉医药科技（苏州）有限公司增资暨关联交易的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、误导性 陈述或者重大遗漏。 一、关联交易概述 为夯实公司在创新药领域的战略布局，强化公司核心竞争力，安徽安科生物工程（集 团）股份有限公司（以下简称"公司"）拟以自有资金3,000万元人民币对参股公司博生 吉医药科技（苏州）有限公司（以下简称"博生吉公司"）进行增资，认购博生吉公司 新增注册资本11.9062万元。本次增资完成后，公司持有博生吉公司21.4121%的股权。 鉴于公司与博生吉公司存在关联关系，根据《深圳证券交易所创业板股票上市规则》 规定，本次交易构成关联交易，但不构成《上市公司重大资产重组管理办法》规定的重 大资产重组。本次关联交易事项已经独立董事专门会议及第八届董事会战略与投资委员 会事前审议通过，本事项已经全体独立董事过半数同意，并经公司于2025年11月11日召 开的第八届董事会第二十三次会议审议通过，无需提交公司股东大会审议。 二、标的公司（关联方）基本情 ...